$TWST

Green Paula sold $75K of TWST

Green Paula (SVP of Human Resources) sold 1,399 shares of Twist Bioscience Corp (TWST) at $53.26 on 2026-05-21.

Original reporting
SEC EDGAR · Green Paula
Published May 26, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Bearish
medium confidence
Mentioned
$TWST
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishLow
01

Why it matters

Insider selling can influence short-term sentiment, but without accompanying corporate events (earnings, trials, contracts, litigation, or M&A), trading impact is usually modest.

02

Market read

A single insider open-market sale is disclosed; expect limited, sentiment-driven impact unless corroborated by other company-specific news.

03

What to watch

No 10b5-1 plan is stated, but the filing alone doesn’t confirm intent; also, the transaction size may be immaterial versus typical daily volume and institutional ownership.

Relevance 6/10Timing: Immediate (filed 2026-05-26) but likely limited follow-through; treat as sentiment-only unless additional news appears.

Background

The article is an SEC Form 4 insider transaction disclosure for Twist Bioscience, reported via EDGAR.

Company-level read

Ticker impact

$TWSTBearishMedium confidence
Context

Twist Bioscience disclosed an SVP of Human Resources selling 1,399 shares in an open-market transaction on 2026-05-21.

Expected impact

Near-term bias to the downside is possible, but magnitude is likely limited given it’s a small, single-insider sale.

Evidence & confidence

Form 4 insider sales can be interpreted as risk/valuation signals, yet the filing provides no earnings, guidance, deal, or regulatory trigger; share count/value are relatively small and not clearly tied to new information.

Market effects

Minimal; insider transactions typically do not change biotech/biomanufacturing sector fundamentals.

None indicated; this is a US-listed company insider disclosure.

None indicated; no international deal/regulatory action mentioned.

Counterpoint

The sale may be routine liquidity/compensation-related rather than a bearish signal, especially since insider sales are common and not always information-driven.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider sale by an SVP of Human Resources.

  • Green Paula

    SVP of Human Resources who sold 1,399 shares open-market on 2026-05-21.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.